CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized ASPECT multicenter study from the United Kingdom reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The trial investigated long-term daily high doses of esomeprazole (80 mg or 20 mg daily) together with aspirin (300 mg) among 2563 patients who had Barrett’s Esophagus (BE) and were therefore at high risk of the disease.
Although the study focused on people with Barrett’s Esophagus, lead study author Janusz Jankowski, MD, PhD, Deputy Vice Chancellor, Royal College of Surgeons, Ireland and Consultant Clinical Adviser, National Institute for Health and Care Excellence, UK told the Audio Journal of Oncology he believed that any person with heartburn could consider taking a high-dose proton pump inhibitor and aspirin after speaking with their doctor. But he warned that patients should not self-medicate since the benefits so far had been found in the specific subset of patients who had BE.Jaanusz Jankowski AJO PRODUCTION MASTER 8'54
The post Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin appeared first on AudioMedica.com.
CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, multicenter phase III trialreported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Although fewer tumors could be resected in patients treated with preoperative therapy compared with those on standard care (down from 72 to 62 per cent) there was a markedly increased rate of complete resections, said study author Geertjan Van Tienhoven MD, PhD, a radiation oncologist at the Academic Medical Center in Amsterdam, Netherlands, who is a member of the Dutch Pancreatic Cancer Group. He discusses the PREOPANC-1 study implications with the Audio Journal of Oncology.
180722 Geertjan Van Tienhoven AJO Production Master
The post Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer appeared first on AudioMedica.com.
CHICAGO—Patients with newly-diagnosed hormone-sensitive metastatic prostate cancer (mPC) who had prostate radiotherapy (RT) before their androgen deprivation therapy (ADT) lived longer than those treated with standard ADT alone in a retrospective analysis—the largest single-center experience to date of primary tumor-directed RT in mPC—reported to the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
After adjusting for the baseline demographics there was an association between receipt of prostate radiotherapy and improved overall survival according to lead author Scott Carlyle Morgan, MD MSC, a radiation oncologist at the Ottawa Hospital Cancer Centre, University of Ottawa, Canada.
He said the findings were “consistent with the hypothesis” that radiotherapy directed to the primary tumor may have altered the natural history of metastatic hormone-sensitive prostate cancer. But he tells the Audio Journal of Oncology this was by no means definitive and he awaits results of the randomized studies.Audio J Oncology Scott Morgan PRODUCTION MASTR
The post Can Initial Radiotherapy Improve Survival with Prostate Cancer? appeared first on AudioMedica.com.
CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatthe 2018 Annual Meeting of the American Society of Clinical Oncology. (https://meetinglibrary.asco.org/record/160671/abstract)
Lisanne F van Dessel MD, a medical oncologist at Erasmus Medical Center Cancer Institute in Rotterdam, The Netherlands, tells the Audio Journal of Onclogy that while their research confirmed that this disease was complex and unstable they had found potentially actionable targets waiting to be studied for therapeutic use which were also likely to be prognostic, predictive or both.Lisanne F van Dessel AJO Production MASTER
The post Whole Genome Sampling Identifies Targetable Prostate Cancer Subgoups appeared first on AudioMedica.com.
CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported in a poster session at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Co-author Graham M Poage PhD, a scientist with the Biotheranostics Company based in La Jolla, California tells the Audio Journal of Oncology about the “Breast Cancer Index” (BCI) test—a reverse transcription polymerase chain reaction (RT-PCR) 11-gene assay—was an endocrine-therapy decision-making tool that had identified very low risk—patients who had 20-year breast cancer specific survival of 98 per cent—a significant proportion of patients who, potentially, could be spared extended endocrine therapy because their risk is so low that continued therapy is unlikely to benefit [them].Graham Poage ASCO AJO Production MASTER
The post Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer appeared first on AudioMedica.com.
CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
In a poster presentation at ASCO Sarah Bateni MD, a surgery resident at the University of California Davis Medical Center in Sacramento, reported survival outcomes from an analysis of National Cancer Database (NCDB) records of 11,406 men who had stage one, two or three breast cancer between the years 2004 and 2015. She discusses the findings with the Audio Journal of Oncology in the company of her colleague, Candice A. M. Sauder, MD, MEd, a Breast Surgical Oncologist at University of California Davis Medical Center.
Sarah Bateni & Candice Sauder AJO
The post Superior Survival in Conservatively Treated Male Breast Cancer appeared first on AudioMedica.com.
CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number and quality of discussions about age-related concerns in comparison with usual care and also resulted in higher scores of patient satisfaction—which the investigators regarded as paramount among therapy outcomes. (https://meetinglibrary.asco.org/record/159519/abstract)
In a media briefing about the study held at the 2018 Annual Meeting of the American Society of Clinical Oncology lead author Supriya Gupta Mohile MD MS, the Wehrheim professor of medicine and surgery and director of geriatric oncology at the University of Rochester, New York, emphasized the pivotal role of GA when treating older patients for their late-stage cancers. She talks with the Audio Journal of Oncology.
Supriya Gupta Mohile AJO INTERVIEW Production MASTER
The post Geriatric Assessment Improved Outcomes for Older Patients with Cancer appeared first on AudioMedica.com.
CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa Clara, California. The findings—using the generalized competing event (GCE) assessment model that balanced the risk of cancer death against non-cancer death—has prompted a call to reassess the influence of gender on treatment decision-making.
Study author Jed A. Katzel MD, a medical oncologist with Kaiser Permanente in Santa Clara, talks with the Audio Journal of Onclogy about his new data from GCE modeling he reported at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
(Abstract LBA6002: Are women with head and neck cancer undertreated?)
Commenting on the findings ASCO Expert Joshua A Jones, MD MA, a radiation oncologist at the Perelman School of Medicine at University of Pennsylvania in Philadelphia said: “We don’t know why women are getting less treatment and having worse outcomes and we need to find out. Though these findings are specific to California the disparities we see are startling and worth considering in treatment discussions in everyday practice.”
Jed Katzel AJO PRODUCTION MASTER
The post Gender Disparity in Head and Neck Cancer Treatment and Outcomes appeared first on AudioMedica.com.
CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control group of patients receiving platinum-based chemotherapy in the open-label, phase three KEYNOTE-042 study reported at the American Society of Clinical Oncology (ASCO) annual meeting plenary session. https://meetinglibrary.asco.org/record/165950/abstract
Principal author of the study, Gilberto Lopes MD, Associate Professor of Clinical Medicine at the University of Miami’s Sylvester Comprehensive Cancer Center tells the Audio Journal of Onclogy patients treated with pebrolizumab monotherapy lived a median of four to eight months longer than those who received chemotherapy and had fewer severe side effects than with chemotherapy (18 per cent as compared with 41 per cent).
The post Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer appeared first on AudioMedica.com.
CHICAGO—Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA mutation-associated breast cancers in a study from Israel reported in a poster session at the American Society of Clinical Oncology 2018 annual meeting.
(Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer.)
Jewish women, high risk
Ella Evron MD, a medical oncologist at the Kaplan hospital in Zerifin, Israel, said that in Israel they saw many patients with BRCA-associated breast cancer because three “founder mutations” are commonly detected in Ashkenazi Jews who are at very high risk of developing breast cancer. She tells the Audio Journal of Oncology about the opportunity to study prophylactic radiotherapy because women increased risk of getting contralateral breast cancer were declining prophylactic surgery because of the fear of its impact on their lives.Ella Evron PRODUCTION MASTER for AJO
The post Radiotherapy Cuts BRCA-Associated Contralateral Breast Cancer Risk appeared first on AudioMedica.com.
© 2009 - 2018 Ebling Library, UW-Madison
750 Highland Ave, Madison, WI, 53705-2221